- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.12.25 | Pasithea Therapeutics Corp. - 8-K, Current Report | - | SEC Filings | ||
| 08.12.25 | Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright | 2 | Investing.com | ||
| PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.12.25 | Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock | 3 | GlobeNewswire (USA) | ||
| 28.11.25 | Pasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise | 1 | RTTNews | ||
| 28.11.25 | Pasithea Therapeutics Prices $60 Mln Public Offering To Advance MEK Inhibitor, Stock Up | 4 | RTTNews | ||
| 28.11.25 | Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock | 2 | GlobeNewswire (USA) | ||
| 26.11.25 | Pasithea Therapeutics Corp. - S-1/A, General form for registration of securities | 14 | SEC Filings | ||
| 25.11.25 | Pasithea Therapeutics Corp. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | ALS Association awards $1 million to study Pasithea's PAS-004 in ALS | 2 | Investing.com | ||
| 24.11.25 | Pasithea reports positive safety data from PAS-004 cancer trial | 7 | Investing.com | ||
| 21.11.25 | Pasithea reports positive PK data for PAS-004 tablet formulation | 1 | Investing.com | ||
| 21.11.25 | Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients | 220 | GlobeNewswire (Europe) | -- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with... ► Artikel lesen | |
| 20.11.25 | Pasithea meldet positive Zwischendaten für MEK-Inhibitor in Krebsstudie | 5 | Investing.com Deutsch | ||
| 20.11.25 | Pasithea reports positive interim data for MEK inhibitor in cancer trial | 1 | Investing.com | ||
| 20.11.25 | Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study | 176 | GlobeNewswire (Europe) | -- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge... ► Artikel lesen | |
| 18.11.25 | Pasithea Therapeutics Corp. - S-1, General form for registration of securities | - | SEC Filings | ||
| 13.11.25 | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11.25 | Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients | 114 | GlobeNewswire (Europe) | MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
| 04.11.25 | Pasithea Therapeutics Corp. - 8-K, Current Report | - | SEC Filings | ||
| 27.10.25 | Pasithea Therapeutics passt Vergütung für Führungskräfte an und vergibt Aktienoptionen | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,290 | -5,56 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| ABIVAX | 99,20 | -9,65 % | EQS-News: ABIVAX: Abivax Provides 2026 Corporate Outlook | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Provides 2026 Corporate Outlook
07.01.2026 / 22:05 CET/CEST
The issuer is solely responsible for the content of... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 13,550 | -5,38 % | Adaptive Biotechnologies: Tochtergesellschaft sichert sich bis zu 15 Millionen US-Dollar in Serie-A-Finanzierung | ||
| GENPREX | 2,000 | 0,00 % | Genprex, Inc.: Genprex Provides Clinical Update on Diabetes Gene Therapy Program | Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies
AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex,... ► Artikel lesen | |
| CIDARA THERAPEUTICS | 190,00 | 0,00 % | XFRA 20D0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCIDARA THERAPEUT.INC... ► Artikel lesen | |
| REZOLUTE | 1,930 | -3,50 % | Rezolute, Inc.: Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism | Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward... ► Artikel lesen | |
| SPRUCE BIOSCIENCES | 73,70 | -6,21 % | Spruce Biosciences secures up to $50M in growth capital | ||
| GALECTO | 20,370 | -5,26 % | Leerink Partners initiates coverage on Galecto stock with Outperform rating | ||
| UNICYCIVE THERAPEUTICS | 6,120 | +1,83 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) | LOS ALTOS, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients... ► Artikel lesen | |
| FIBROBIOLOGICS | 0,286 | -3,38 % | FibroBiologics, Inc.: FibroBiologics CEO Issues Letter to Shareholders | HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,830 | +0,73 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,350 | +26,99 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 23,280 | +50,48 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| QIAGEN | 41,290 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| ALUMIS | 18,170 | +1,40 % | What's Going On With Alumis Stock Thursday? |
Das Unternehmen PASITHEA THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,926 Euro und damit -5,53 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASITHEA THERAPEUTICS CORP finden Sie auf Wallstreet Online.